Saturday, July 11, 2026

pharma · Asthma · Respiratory Syncytial Virus Infections

GSK Glaxo Smith

GSK Glaxo Smith is a pharma organization headquartered in SAINT-AMAND LES EAUX, FR. Primary therapeutic focus areas include Asthma, Respiratory Syncytial Virus Infections, Hepatitis B, Chronic, Neoplasms, Influenza. Nova

637 r Aulnois, Saint Amand les Eaux, 59 59230, FR, SAINT-AMAND LES EAUX HQ
30 Employees
NMPA registrant Type
Company details
Status
Public
HQ
637 r Aulnois, Saint Amand les Eaux, 59 59230, FR, SAINT-AMAND LES EAUX
Employees
30
Programs
205
Drugs
194
Patents
0
Clinical program

Tafenoquine

Phase 3 · small molecule · Malaria, Vivax

Tafenoquine for Malaria, Vivax is a Phase 3 program (small_molecule) at GlaxoSmithKline with 2 ClinicalTrials.gov record(s).

← All GlaxoSmithKline projects Phase 3 small molecule completed

Internal code 113577

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
GlaxoSmithKline
Phase
Phase 3
Modality
small_molecule
Indication
Malaria, Vivax
Status
completed
Trials
2